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1. Introduction 
In an increasingly aging population, where aesthetics plays an important role in society, the 
loss of bone and teeth due to disease or trauma places a large burden on healthcare systems 
worldwide. It is estimated that more than 2.2 million grafting procedures are performed 
annually to repair bone defects in orthopedics, neurosurgery and dentistry (Giannoudis et 
al, 2005). Following surgical intervention the use of bone grafts / substitute materials or 
distraction osteogenesis (DO) for the expansion of the maxialla are current approaches to 
facilitate bone regeneration. What is regeneration and how is it defined? Regeneration can 
be defined as ”the reproduction or reconstruction of a lost or injured part of the body in 
such a way that the architecture and function of the lost or injured tissues are completely 
restored” (Bosshardt et al, 2009), and as such it is necessary to consider the cells that are 
involved to produce the destroyed tissues, how can these cells be stimulated and is a space 
filler required to support the cells and to hold signaling molecules? Bone formation is a 
complex and dynamic process involving the interactions between cells and the surrounding 
milieu. Repair occurs before regeneration but where healing occurs first without restoration 
of function. The current chapter considers clinical approaches, cases and requirements for 
bone regeneration and brings it together with a biological perspective of the cellular and 
biomolecular interactions necessary to stimulate new bone formation. Given the increasing 
need for grafting procedures and the limitations to current grafting techniques the future 
applications of tissue engineering approaches are finally discussed. 
2. Clinical applications 
Reconstructive surgery for bony defects in the oral and maxillofacial region is a challenge. 
The gold standard for reconstructive surgery remains autogenous bone grafting that is 
osteoconductive and osteoinductive, and from an immunological point of view safe. Donor 
sites are available either intra- or extra orally. The intraoral harvesting sites are in the 
maxillary tuberosity and in the mandibular ramus, retromandibular area and the 
symphysis. The bone is often of cortical nature and the volume limited. Harvesting can be 






from extra-oral sites is required when larger amounts are required. The iliac crest, tibia, 
costochondral bone or calvarium bone are common donor sites but general anesthesia and 
hospitalization of the patient is needed. The bone is both of cortical and 
cancellous/trabecular nature. When it is not possible to harvest bone due to the patient’s 
medical history or limited resources, DO, a relatively new technique in the field of oral and 
maxillofacial surgery has been developed. This technique has also been useful in 
reconstructive surgery for genetic anomalies.  
2.1 Reconstruction of resorbed alveolar crests 
Edentulous severely resorbed maxillas are a major problem for patients when prosthodontic 
treatment and dental implants are necessary. The standard procedure installs the implants 
vertically in the alveolar crest with the implant totally covered by bone. The bone volume 
needs to be at least 10 mm in the vertical dimension and 4 mm in the horizontal aspect in the 
maxillary alveolar crest with this technique. In patients with less bone volume bone grafting 
is an alternative. Tilted implants were first presented by Mattsson and colleagues as an 
alternative method to bone grafting in severely resorbed alveolar crest, classes V and VI 
(Mattson et al 1999). The method of tilting the implants was used to reach the maximum 
length of the prosthodontic bridge. Recently, we presented a 10-year follow-up study on 
patients treated with this technique. The success rate was 97 % (Rosén et al 2007). One 
reason for the high success rate could be attributed to the use of longer implants, thereby 
improving the anchorage in dense bone compared to conventional implant treatments. 
Another advantage was that the prosthetic construction could be more posteriorly directed 
in the arch and result in the equalisation of loading across the bridge. Krekmanow and 
collaborators have reported biomechanical measurements in tilting implants, which showed 
no negative effects on load distribution in the fixed prosthesis constructions (Krekmanow et 
al 2000). Furthermore, the method by which implants are tilted is relatively easy for the 
surgeon to perform and reduces the patient’s treatment time (Fig. 1).  
 
Fig. 1. X-ray, patient treated with tilted implants. 
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2.2 Sinus lift  
The first use of bone grafting to the maxillary sinus was presented in the 1960s by Boyne 
(Boyne 1969). He performed a so-called Caldwell-Luc opening, where a fenestration of the 
bone to the maxillary sinus made it possible to elevate the sinus membrane. Autogenous 
bone and marrow grafts were placed on the sinus floor. Approximately three months after 
surgery an increase of osseous tissue was seen. In a review by Triplett and collegues 
(Triplett et al 2000), they described the material choices for sinus augmentation, and 
concluded that autogenous bone was the best choice as it was osteoinductive, 
osteoconductive and contained osteoblasts and osteoprogenitor cells. The technique of sinus 
grafting has been used for placement of dental implants since then.  
Sinus lift with an osteotom is another even easier technique to perform, when maxilla bone 
is moderately resorbed. The technique involves a series of increasingly wide osteotomes, 
which allows site preparation for the implant while also expanding the apical portion of the 
alveolus into the sinus. The elevated sinus membrane remains intact and bone forms 
beneath the elevated membrane, commonly 3-4 mm of floor height is effectively gained. The 
bone cells migrate from both the base of the sinus maxillaries and from the bone chip that is 
uplifted into the sinus. From the start the bone height has to be at least 4 mm so that a 9 or 
11 mm implant can be installed. The concept of “tenting-up” the membrane in both the 
sinus floor and the nasal floor was first described by Brånemark (Brånemark et al 1984).  
A 2-3-year follow-up study evaluated the survival rate of dental implants placed in partially 
or totally edentulous maxillae, with moderately resorbed bone (Dabirian and Rosén 2004). 
The implants were placed directly in the bone of the maxillae or in bone graft sites in sinus 
maxillaries using the sinus lift technique with an osteotom. The number of healthy patients 
treated with implants in the study was 126. The total number of implants was 232, 1 - 6 
implants in each patient. Each patient was examined yearly with oral inspection and x-ray. 
The follow-up period was 2 - 4 years (mean of 3 years). The results showed satisfactory 
implant survival rates of 99.6 % after at least 2 years of clinical function. Only one implant 
was reported to have failed. However, in the radiological examinations, marginal bone loss 
of greater than 0.2 mm per year was observed in 22.8 % of the cases. The study showed that 
maxillary sinus floor grafting could be performed where the maxillary bone does not offer 
adequate space for the implants without affecting the survival rate of these implants.  
2.3 Bone grafting 
Bone grafting is a frequently used method where autogenous bone is transplanted to 
defected jaws (Nyström et al 2004). The harvested bone can be placed as inlays or onlays 
both in the maxilla and in the mandible. Inlay means when the bone is placed inside, for 
example in the sinus maxillaries as a bone chip, particulate bone or in between two bony 
fragments. Onlay means when a bone block is fixed with titanium plates and screws on the 
buccal or lingual part of the alveolar ridge. However, bone grafting is time- consuming due 
to the extra time needed for the graft to augment until time for dental implant installation, 
typically 6 months. After the grafting procedure, the bone block becomes almost necrotic 
and will be incorporated by revascularization induced by the inflammatory reaction during 
the first week after implantation, the healing phase. In the case of cancellous particulate 






surrounding tissue occurs faster. It is incorporated quicker but there is also the risk of a 
faster resorption. Grafting will often necessitate general anesthesia and hospitalisation, 
which is costly to national healthcare systems. Despite the high success rate for the tilted 
implant procedure, today the gold standard is still autogenous bone grafts; not only for 
implant treatment but for all kinds of osseous defects in oral and maxillofacial regions. One 
side effect is that the bone cannot be expanded in the vertical height when using the onlay 
technique, only in the horizontal dimension which makes the alveolar crest wider so there is 
enough space for the implants. The inlay technique, however, can expand the alveolar bone 
in the vertical dimension in the maxilla. A Le Fort I osteotomy is used to expand the space 
for the transplanted autogenous bone and stabilization of the transplanted bone is made by 
titanium plates and screws (Fig. 2).  
  
Fig. 2. Bone grafting, bone is taken from the iliac crest, and the Le Fort I technique is used to 
expand the vertical height in the maxilla. 
This technique can be useful when the sagital dimension is not optimal for dental implant 
treatment. With the Le Fort I osteotomy the maxilla can be moved forward for optimal 
occlusion. Side effects, such as postoperative problems with the graft or host site morbidity 
can be observed as well as resorption of the bone if an extended healing time is required. It 
is very important to cover the osteotomy with a tension free flap otherwise, a gap in the 
incision area will be the result and the chances of an infection or the resorption of the 
transplanted bone increases. These surgical procedures also entail some risks in the form of 
nerve damage (Kahnberg, 2010). 
2.4 Synthetic bone building technique 
Bone-building therapies, such as synthetic bone, allogenic, or bone from different species, 
xenogenic, have been used extensively in the past with satisfactory results. However, the 
healing time for biomaterial grafts is longer than for autogenous bone and it may also give 
rise to rejection and infection. Rejection of the bone or possible transmission of infections 
from these types of bone-building therapies is a danger (Maiorana, 2010).  
2.5 Distraction osteogenesis 
Distraction osteogenesis (DO) is a method for either restoring atrophic jaws in the vertical 
dimension or for expanding congenital defected jaws in the orofacial region (Cheung et al 
2010). DO is a clinical tissue engineering method with huge possibilities, even to treat severe 
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deformities in the craniofacial area. Patients with hemi-facial asymmetries, extreme 
retrognatic maxillas or mandibles can be adjusted to normal positions. The device can be 
intra- or extraorally fixated with titanium screws in the bone. The major advantages are that  
bone grafts are not necessary and the technique allowing the soft tissue to expand in the oral 
region. The technique consists of five phases, the osteotomy, the latency, active distractor, 
consolidation and remodeling. The osteotomy triggers a biological process of bone repair. A 
blood clot appears and will be replaced by granulation tissue which consists of 
inflammation cells. Fibroblasts, collagen and invading capillaries fill the distracted bone 
space and stimulate the osteocytes. This technique can even be used in temporomandibular 
joint (TMJ) reconstruction, in cases with ankylosis where the condyle is resected. The TMJ 
distraction creates a neocondyle in the bone of ramus mandibulae, the bone moves 
gradually towards the glenoid fossa and the normal anatomical structures will be restored. 
Long term stability of the TMJ has been reported (Cheung et al 2007).  
DO is a two-stage surgical technique and can be used when teeth are missing and the 
alveolar ridge needs to be vertically expanded with bone before dental implants are placed 
(Cano et al 2006) or in the cases of an open bite with good occlusion in the molar region of 
the jaws when conventional orthognathic surgery is not an alternative. A reliable patient is 
needed who must expand the device each day and it also necessitates a long retaining 
period including orthodontic treatment.  After the retaining period the device has to be 
removed surgically. Infections, bone morbidity and distracter fractures are side effects that 
have been reported (Saulacic et al 2009).  
Recently, two patient cases in our clinic with open bite and normal occlusion in the 
premolar and molar region were treated with the osteodistraction technique. Patient 1, a 22-
year old male with a three-year follow-up and patient 2, a 40-year old female with a two- 
year follow-up were treated. The alveolar ridge was vertically expanded in the frontal 
maxillary area in both cases. The intra orally distraction devises were surgical inserted 
under general anesthesia (Fig. 3).  
 
Fig. 3. The distraction device surgically inserted in the frontal maxilla in patient 1. 
After a couple of nights in hospital the patients went home and after approximately one 






the maxillary frontal regions were expanded to a normal occlusion. The orthodontic 
treatment started whilst the distraction device remained for a three month retaining phase. 
After a year, the orthodontic treatments were finished and good results were obtained in both 
patients. The patients were satisfied with the results and no side effects were seen (Fig. 4).  
 
Fig. 4. Pre- and postoperative close up pictures of patient 2 with an open bite and treated 
with DO. 
Patient 1 developed a necrotic tooth pulp after two years, which had to be endodontically 
treated, probably a side effect of the orthodontic treatment. A three year follow-up study 
will soon be reported (Rosén et al in manuscript).  
2.6 Surgically assisted rapid maxillary expansion (Sarme) 
Orthopedic maxillary expansion (OME) is a common method used in children for treating 
uni- or bilateral cross bites, cleft lip and palate, and patients with maxillary teeth 
crowding to gain arch length. In teenage children or in adults where the bone is mature 
and therefore harder, limited expansion occurs only with dental changes. Surgical 
procedures such as Le Fort I osteotomy for widening the maxilla in a transverse 
dimension has been an alternative to OME in teenage children and for adults. The 
combined surgical and orthodontic treatment for maxillary expansion with only tooth 
anchorage often show post retention relapses with the Hyrax-type expander. Several 
types of surgical assisted rapid maxillary expansion (SARME) devices with bone 
anchorage have thereafter been presented, the transversal palatinal Surgi-Tec, the 
Rotterdam Palatal distracter, the Magdeburg palatal distracter and the Smile distracter. 
Recently, a three year follow-up study was reported where OME or SARME were 
compared with a control group. The control group consisted of untreated, skeletal Class 1 
subjects matched to the OME group in order to assess the effects of normal skeletal 
growth. The study showed that both the OME and the SARME procedures remained 
stable after three years with some amount of post retention relapses compared with the 
control group (Kurt et al 2010). In our clinic, we went one step further using a device with 
both tooth and bone anchorages (Fig. 6). A long time follow-up study of this technique 
will soon be presented. The study included 43 patients treated with the tooth and bone 
anchored device. Palatinal expansion up to 15 mm occurred, in patients where the canines 
had supra position and no space at all in the arch (Rosén et al, in manuscript).  
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Fig. 6. A SARME device with both teeth and bone anchorages. Palatinal screws are hidden 
on each side under the posterior part of the device 
2.7 Osteogenesis imperfecta 
Osteogenesis imperfecta (OI) is an inherited genetic disorder. The connective tissues are 
affected throughout the whole body, including the dentin of the teeth. To date, seven types 
of OI have been identified varying from the mild Type I OI to the moderate Types IV and 
VI, severe Types III, V and VII to lethal Type II (Martin and Shapiro, 2007). Multiple 
fractures of long bones are frequently observed as well as disturbances of the permanent 
dentition. Orthognathic surgery in patients with OI is rare but necessary to correct the 
malocclusion for functional and esthetic reasons. Most cases result in a successful outcome 
with stable and good dental occlusion. Two patients probably with severe types I and IV OI, 
and malocclusion class III with retrognathic maxilla and prognathic mandible, were treated 
with orthodontic treatment and bimaxillary surgical correction (Rosén et al 2011).  
Patient 1, a 26-year old male with most likely OI type IV was treated. Since childhood he 
had been treated for 18 fractures of the limbs and hips. The analysis indicated advancement 
of 8 mm of the maxilla and a setback mandible of 4 mm. The surgical procedure was 
planned with certain precautions with a two step model. Firstly, a Le Fort I osteotomy 
where a stable occlusion was planned for  so the surgery could be interrupted in case the 
bone was too brittle. Secondly, a setback vertical ramus osteotomy followed by an 
intermaxillary fixation for five weeks. We tested the bone in the maxilla with titanium 
screws before any osteotomies were performed to ensure their function in the soft bone 
before continuation. We planned to use wires or a halo frame for stabilization if the bone 
proved to be too soft. The surgical outcome in patient 1 was good and the surgery was made 
in one session. The maxillary bone was thin and teeth were brittle but the orthodontic 
anchorage was stable enough to fixate the jaws together and the titanium screws remained 
stable in the bone when the titanium plates were fixed over the osteotomies.  
Case 2, a 22-year old male with OI severe type I was planned for a 10 mm advancement of 
the maxilla with a Le Fort I osteotomy and 6-7 mm set back with a vertical ramus osteotomy 






was no need for bone graft during surgery and the operation followed a routine fashion and 
was completed after five weeks of intermaxillary fixation. We concluded that it was possible 
to perform combined orthodontic and orthognathic surgery in patients with OI despite the 
greater risk of complications such as fractures in the soft bone and loss of orthodontic 
anchorage in brittle teeth. The treatments were successful in both cases with follow-up times 
of five to six years (Fig. 7, Rosén et al 2011). 
   
Fig. 7 a and b. Surgically treated patient with OI. The patient no. 1 underwent bimaxillary 
surgery and the profile photos are pre-and postoperative. 
3. Biological considerations 
The dynamic interplay between the cells and the environment is essential to ensure 
successful bone formation and regeneration, a feature easily forgotten during the 
establishment of new clinical strategies. Therefore to fully understand bone grafting and 
regeneration an appreciation of bone mineralization, and the interplay with the biochemical 
environment is necessary. In many cases after maxillofacial surgery, wound healing occurs 
before new bone is deposited. Bone formation is a carefully balanced process involving the 
secretion of an organic pre-mineralized matrix, osteoid, that becomes mineralized with 
inorganic hydroxyapaptite (HAP) crystals and its subsequent resorption and remodeling. 
The interactions with the surrounding biochemical milieu stimulate cell migration, 
adhesion, proliferation, differentiation, transcription and translation. Resulting in the 
synthesis and secretion of an extracellular matrix (ECM) that acts as a scaffold for mineral 
deposition and nucleation, and serves to sequester and protect growth factors.  
3.1 Wound healing 
Wound healing is a unique and complex system, where the healing of both soft and hard 
tissues needs to be fully integrated. For this to occur a coordinated series of events must be 
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induced, i) stimulation of an initial inflammatory response, ii) the recruitment of specific cell 
types and iii) induction of their proliferation leading to bone formation. A model has been 
devised for wound healing in the epithelia but it is also relevant in this context, particularly 
with DO (Wikesjsö et al, 2010). Initially, clots form followed by early stages of inflammation 
with the infiltration of inflammatory cells, such as neutorphils and monocytes into the clot. 
This takes place just hours after damage and cleanses the wound of bacteria and necrotic 
debris. After a few days, the late phase of inflammation is initiated along with macrophages 
infiltrating into the wound. Macrophages assist the formation of granulation tissue and the 
release of growth factors that stimulate fibroblasts. The granulation tissue matures 
becoming rich in cells and the collagen-rich ECM provides a suitable environment for 
further cell propagation and reconstruction of the vasculature prior to bone formation. 
3.2 Bone formation 
Bone formation occurs by two distinct condensation processes; endochondral, which forms 
the long bones and intramembraneous that results in the flat bones of the jaws and calvaria. 
Endochondral bone formation occurs when mesenchymal stem cells (MSCs) migrate and 
condensate at a high density at regions where skeletal rudiments will develop. MSCs 
differentiate into chondrocytes to form an avascular anlagen, into which they secrete an 
ECM rich in type II collagen and aggrecan, and express typical chondrocytic transcription 
factors, such as Sox 5/6/9. As proliferation ceases, the epiphyseal growth plate begins to 
form with the cells becoming hypertrophic, synthesizing type X collagen and blood vessels 
finally penetrate into the cartilage template. The hypertrophic chondrocytes undergo 
apoptosis and are replaced by osteoblasts recruited from the perichondrium to form the 
bone collar and together with bone elongation create the bone marrow space. In 
comparison, intramembraneous ossification results from the direct condensation and 
differentiation of MSCs into osteoblasts in regions that are rich in blood vessels. The 
resulting woven or primary bone forms rapidly, particularly during embryogenesis, in the 
case of DO, after fracture healing and during adaptive bone gain after mechanical loading. 
Despite these two distinct formation pathways both types of bone share some common 
molecular and cellular control mechanisms.  
3.3 Bone cell differentiation 
Biomineralization is a dynamic process driven by active osteoblasts that initially secrete an 
osteoid that eventually becomes mineralized. The mature cells are polarized and cuboidal, a 
proportion of which are termed bone-lining cells and become flattened and align along the 
bone surface. Whereas the remainder become entrapped and embedded within the forming 
mineralized tissue within the lacunae of the matrix called osteocytes. The precise function of 
osteocytes remains to be clarified however evidence suggests that the cells have a role in 
response to mechanical stimuli, as a mechanoreceptor (Aarden et al, 1994). 
Osteoblast progenitors are derived from MSCs, which originate as pericytes along the blood 
vessels within the bone marrow in a niche that is finely balanced with hematopoiesis 
(Bianco et al, 2011). MSC differentiation gives rise to a number of different lineages that 
acquire specific phenotypes under the control of specific regulatory factors. Characterization 






proliferation stage, matrix maturation stage and mineralization stage. During the first phase 
of growth and proliferation the cells exhibit high mitotic activity and actively express cell-
cycle associated genes. At this time ECM associated molecules are synthesized including 
collagen type I, osteopontin (OPN) and fibronectin. Collagen type I continues to be 
expressed with proliferation but at low levels whereas the other ECM proteins are all down-
regulated. As the cells move into the second stage of matrix maturation, alkaline phosphate 
levels dramatically increase and there is considerable secretion and organization of the 
organic ECM in preparation for the final phase of mineralization and the deposition of HAP 
crystals. The secreted ECM molecules play a considerable role in this dynamic process, 
including collagen type I, glycoproteins, sialoproteins and proteoglycans, and their roles 
will be discussed in more detail below.  
Each of the phases of osteoblast differentiation is characterized by a set of specific genes and 
regulatory molecules that allow progression into the next stage (Marie, 2008). The initial and 
key transcription factor is Runx2, also known as Core-binding factor alpha 1, a member of 
the Runt-related factors (Runx) family of transcription factors. Runx2 activates vital bone 
ECM genes, including collagen type 1 alpha 1 (COL1A1) and osteocalcin (OCN). It is 
important to note that Runx2 is also expressed by cells other than osteoblasts, including 
chondrocytes, T-cells and other mesenchymal cells. However, two separate promoters have 
been identified; an upstream promoter that specifically drives the expression of osteoblast-
specific isoforms, whereas the downstream promoter activates Runx2 isoforms in T-cells, 
although some expression has been identified in osteoblasts (Harada et al, 1999). Runx2 is 
essential for both endochondral and intramembraneous bone formation, as targeted 
disruption of the gene results in a complete lack of bone formation in both processes 
(Komori et al, 1997). On the other hand, over expression of Runx2, such as by skin 
fibroblasts, which do not normally express the molecule, exhibit osteoblast-specific gene 
expression (Takeda et al, 2001). In addition to being the initiator of osteoblast differentiation, 
it functions as an inhibitor of progenitor proliferation and is required for terminally 
differentiated osteoblast function. Downstream of Runx2, osterix (OSX, Sp7), a zinc-finger-
containing transcription factor and bone morphogenic protein (BMP) 2-inducible gene has 
been identified as the regulator of the final stages of bone formation (Nakashima et al, 2002). 
In similarity to Runx2, OSX also activates COL1A1 and OCN, and in a transgenic null 
mouse model no endochondral or intramembraneous bone formation was detected. 
Upstream of Runx2 the picture is less clear. A few transcription factors have been identified; 
Twist-1 is down-regulated for Runx2 activation, Msx2 and Bapx1 both regulate the 
expression of Runx2 (Huang et al, 2007). Additional studies have demonstrated the 
importance of signaling pathways that may act in parallel or independently of Runx2 to 
regulate osteoblast differentiation.  
Osteoblasts also influence the differentiation of bone resorbing cells, osteoclasts. Osteoclasts 
derive from the monocytic / macrophage lineage and are multi-nucleated cells. The main 
regulatory pathway involved during osteoclast differentiation is through the receptor for 
activation of nuclear factor kappa B ligand (RANKL) / RANK / osteoprotegerin (OPG) 
pathway. Osteoblasts express RANKL and macrophage-colony stimulating factor (M-CSF), 
which activate a number of signaling pathways in osteoclasts. However, OPG acts as a 
decoy receptor for RANKL inhibiting the RANK /RANKL interaction, and in turn osteoclast 
differentiation. Local and systemic factors, such as parathyroid hormone (PTH) also 
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promote osteoclast differentiation by increasing RANKL expression by osteoblasts. RANKL 
has also been implicated in the regulation of mature osteoclasts. OPG over-expressing 
transgenic mice exhibit severe osteopetrosis, impaired tooth eruption due to the lack of 
osteoclasts (Kong et al, 1999).  
3.4 Extracellular matrix: collagenous and non-collagenous components 
The organic matrix of bone is comprised of 90% collagen type I and additional non-
collagenous components (Table 1), some of which have important functions in bone 
formation. Furthermore, the ECM is a vial source of factors that play crucial roles in cell 
signaling and the modulation of mineralization, such as BMPs. Most of these proteins and 
factors are produced locally by osteoblasts but others, like the serum proteins are 
synthesized elsewhere and delivered to the developing bone via the circulation.  
 
 Extracellular Matrix  
Collagenous Non-Collagenous Enzymes 
Type I γ-carboxyglutamic acid containing 
- OCN, MGP, Periostin 
TNAP 
Type X Glycoproteins - ON, FN, COMP 
MMPs 
- 1,2, 8 and 9 
Type III Sialoproteins - BSP, OPN 
TIMPS 
- 1, 2 and 3 
Type V 
GAG – containing leucine rich repeat proteins 
- Aggrecan, Versican, DCN, BGN, FMD, LM, 
OSAD 
 
 Serum proteins - Fetuin, Albumin  
OCN -osteocalcin, MGP – matrix gla protein, TNAP – tissue non-specific alkaline phosphatase,  
ON – osteonectin, DMP1 – dentin matrix protein 1, FN – fibronectin, COMP – thrombospondin,  
MMP – matrix metalloproteinase. BSP – bone sialoprotein, OPN – osteopontin, TIMP – tissue inhibitor 
of MMPs, GAG – glycosaminoglycan, DCN – decorin, BGN - biglycan, FMD – fibromodulin, LM – 
lumican, OSAD – osteoadherin 
Table 1. Principal ECM-associated molecules implicated in the biomineralization process 
Collagens are responsible for maintaining the structure and function of bone. In particular, 
fibrillar collagens, principally type I, are important in biomineralization, whereby they 
facilitate the formation of an ECM scaffold in which crystal nucleation occurs and 
subsequent crystal elongation spreads through the organized matrix. Disorders that disrupt 
collagen synthesis have significant effects on bone formation. In the case of OI, mutations 
have been identified affecting collagen type I genes, COL1A1 and COL1A2. Collagens play a 
crucial role during boney healing by aiding the formation of early bone spinicles that extend 
from the damaged / surgical site toward the center of the defect. The spinicles form the 
primary mineralization front associated with successful union of the surrounding bones. 
New bone formation associated with DO forms through the deposition of primary bone via 
intramembranous ossification. In a rat model of DO, studies have demonstrated that 
collagen type I is up-regulated ten days after osteotomy, which continues with 






The remaining non-collagenous proteins of bone have been implicated in the modulation 
and regulation of biomineralization. Most are highly anionic and have a strong ion-binding 
capacity. The γ-carboxyglutamic acid containing protein, OCN is known to be one of the few 
molecules that are truly mineralized tissue-specific (Bronckers et al, 1985). OCN acts as a 
regulator of mineralization through the inhibition of spontaneous mineral deposition and 
HAP crystal growth (Romberget al, 1986). In DO rat models, OCN levels have been shown 
to correlate with successful treatment, gradually increasing from mid-activation and 
consolidation (Allori et al, 2008b; Fang et al, 2004). Osteonectin (ON), accounts for 15% of all 
non-collagenous proteins. It is proposed that ON has a role as a nucleator in collagen-
mediated mineralization but also it may have a role in the inhibition of cell proliferation, 
modulates cell-matrix interactions, and binds and regulates HAP crystal growth (Brekken et 
al, 2001). A significant family of non-collagenous proteins is the small integrin-binding 
ligand N-linked glycoproteins (SIBLINGs). All clustered on human chromosome 4, they 
include bone sialoprotein (BSP) and OPN. BSP is osteoconductive, osteoinductive, promotes 
cell attachment, stimulates osteoblast proliferation and differentiation and importantly 
serves as a nucleator of mineralization (Gordon et al, 2007; Tye et al, 2003). The proteoglycan 
family consists of more than 30 proteins that are post-translationally modified with 
glycosylation or the addition of a glycosaminoglycan (GAG) chain. Small leucine-rich 
proteoglycans (SLRPs) have a core protein and contain one or more GAG chains including 
chondroitin or dermatan sulphate, heparin or keratin sulphate. Studies have shown SRLPs, 
in particular chondroitin sulphate-containing decorin and biglycan to bind collagen and to 
regulate HAP crystal growth (Sugars et al, 2003). In addition, osteoadherin (OSAD) is 
currently believed to be mineralized tissue-specific, with a role in inhibiting actively 
proliferating cells, to binding collagen and HAP (Wendel et al, 1998). Furthermore, OSAD 
has been found to have a similar distribution pattern as BSP in rat long bones and calvaria 
(Ramstad et al, 2003). 
The final group of molecules that requires consideration in the ECM are enzymes, 
specifically tissue non-specific alkaline phosphatase (TNAP) and matrix metalloproteinases 
(MMPs). The current belief is that matrix mineralization is initiated through the expression 
of TNAP by osteoblasts. It functions to increase the relative concentration of phosphate by 
inactivating pyrophosphate, so that HAP becomes the main product. In disease states, such 
as rickets and osteomalacia, TNAP is either inactive or expressed at low levels resulting in a 
reduced amount of mineralization (Fedde et al, 1999). An important feature of bone 
formation and repair is the ability to remodel to create an environment and scaffold in 
which mineralization can occur. MMPs and their inhibitors, tissue inhibitors of MMPs 
(TIMPs) fulfill this goal and are designed to specifically degrade particular ECM 
components. For example, collagenases (MMP1) have been involved in fracture healing and 
DO, and gelatinases (MMPs 2, and 9) in osteoclastic remodeling. In addition, matrix 
degradation allows for growth factors and /or signaling molecules sequestered in the ECM 
to be released to act on early by cells (Weiss et al, 2002). MMPs also act to facilitate cell 
migration, influence osteogenesis and vascularization.  
3.5 Growth factors and signaling molecules 
The regulation of osteoblast differentiation, bone formation and turnover involves signaling 
molecules such as growth factors, hormones and cytokines (Table 2). These maybe secreted 
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endogenously by local cells or absorbed from the blood. Growth factors are synthesized as 
biologically inactive propeptide forms and stored in the cytoplasm or ECM. They initiate 
their effect by binding to cell surface receptors and following intricate intracellular signaling 
transduction pathways to transmit signals to the nucleus, resulting in the activation of 
specific target genes that regulate cellular activity and or phenotype. Many act locally or 
systemically and affect target genes in a variety of ways; autocrine, intracrine, paracrine, 
juxacrine, and finally endocrine. All these mechanisms are highly regulated through a 
complex system of feedback loops and interactions involving other growth factors, 
hormones and binding proteins, as well as regulatory factors that act on extra and 
intracellular levels. 
Principal growth factors implicated in bone formation and turnover include the 
transforming growth factor – β (TGF-β) family, BMPs, insulin-like growth factor (IGF), 
epidermal growth factor (EGF), fibroblast growth factor – 2 (FGF2), platelet-derived growth 
factor (PDGF) and vascular endothelial growth factor (VEGF). TGF-β isoforms 1,2 and 3 are 
capable of exerting the same functional activity but with slight structural differences, for 
example TGF-β1 has been observed at sites of osteogeneis but TGF-β’s 2 and 3 at sites of 
chondrogenesis (Schmid et al, 1991). TGF-β’s can stimulate osteoblast migration, and is a 
potent regulator of cell proliferation, cell differentiation and ECM maturation (Janssens et al, 
2005). However, TGF-β’s are unable to initiate the osteoblast and bone formation cascade at 
extraskeletal sites, unlike BMPs. Both TGF-β’s and BMPs act via BMP receptors types I and 
II, and Smad 1 / 5 / 8 molecules. Phosphorylation of the Smads following binding of the 
BMP to the receptor causes translocation into the nucleus in a complex with Smad4, where 
they regulate target genes. BMPs 2, 4 and 7 are collectively known as the osteogenic BMPs as 
they have been shown to induce ectopic bone formation (Bragdon et al, 2011). Regulation of 
osteoblast differentiation results from the interaction of the complex of Smad 1 / 5 / and 8 
with Smad 4 on target genes, specifically Runx2 and OSX. 
 
 Signaling Molecules  
Growth factors Hormones Cytokines 
TGF-β PTH Interferon γ 
BMP Calcitonin Interleukins 1 and 6 
FGF Estrogen Prostaglandins E2 and I2 
Activin A Thyroxine CSF 
PDGF   
IGF-1   
VEGF   
TGF – transforming growth factor, PTH – parathyroid hormone, BMP- bone morphogenic protein, FGF 
– fibroblast growth factor, CSF –colony stimulating factor, PDGF –platelet derived growth factor, IGF – 
insulin growth factor, VEGF –vascular endothelial growth factor 
Table 2. Signaling molecules involved in the regulation of bone formation and bone 
remodeling  
A number of hormones contribute to the regulation of bone formation and turnover. 






calcium storage respectively (Allori et al, 2008a). PTH is secreted in response to decreased 
levels of calcium. Calcium release into the bloodstream following bone destruction by 
osteoclasts stimulates PTH and its downstream effector vitamin D3. PTH stimulates RANKL 
and M-CSF expression in osteoblasts but conversely inhibits OPG synthesis that in turn 
prevents RANKL binding to RANK. The actions of PTH and BMPs are closely linked with 
the activation of the Wnt signaling pathway. The Wnt / β-catenin (canonical) pathway 
governs osteoblast differentiation and is initiated through the formation a receptor complex, 
composed of Frizzled receptors and low density lipoprotein receptor-related proteins 5 and 
6, on the cell surface (Westendorf et al, 2004). Activation of the canonical Wnt pathway 
promotes osteoblast differentiation from MSCs at the expense of adipocytes, leading to 
improved bone strength (Bodine et al, 2006). 
3.6 Mineral composition and mechanisms of biomineralization 
The major mineral component of all calcified tissues is biological apatite, a calcium 
phosphate that is very closely related to the geologic mineral HAP (Ca10(OH)2(PO4)6). In 
comparison to naturally occurring apatite, the mineral of bone differs in a number of 
respects, firstly biological HAP readily incorporates impurities such as CO32-, F-, and Na+ 
into the crystal structure that are absent in pure HAP, second the theoretical 
calcium/phosphate ratio of pure HAP is 1.667 but this can vary from 1.5 to 1.7, leading to 
the term “calcium-deficient”, finally a small percentage of water is present in biological 
HAP, making its crystallinity less than perfect. The skeleton contains 99% of the body’s 
calcium, 35% Na+, 60% CO32- and 60% Mg (Boivin et al, 2003). 
Biomineralization results from two stages; mineral nucleation to form HAP crystals, and 
subsequent HAP crystal growth, both involving the presence of the three-dimensional ECM 
framework. The process by which nucleation is initiated is a constant source of debate and 
include biomineralization foci, calcospherulites and matrix vesicles. Matrix vesicles have 
long been contested as sites of nucleation in bone and recent data suggested that the vesicles 
are present in bone but that they vary in size and the composition (Gorski, 2011). Vesicles 
have also been shown to be present within biomineralization foci (Huffman et al, 2007). 
Biomineralization foci (10-25 micron diameter) are the result of ECM-mediated nucleation. 
These foci are rich in acidic phosphoproteins, such as BSP and bone acidic glycoprotein -75, 
as well as immature collagen type I. Biomineralization foci have been detected in the 
periosteum of developing bones and in primary bone (Gorski et al, 2004).  
3.7 Bone remodeling  
Bone remodeling is a highly controlled and balanced process, ensuring the successful 
replacement of old bone with new through the sequential resorption by osteoclasts and 
subsequent bone formation by osteoblasts. Through this process bone remodeling ensures 
skeletal integrity throughout life. Currently, bone remodeling is considered to occur via 
either targeted or non-targeted remodeling (Eriksen, 2010). Non-targeted remodeling is 
proposed to be modulated by the osteoclasts themselves via hormones such as PTH, 
thyroxine and estrogen and some anti-resportive drugs like bisphosphonate. Whereas, 
targeted remodeling, specifically removes damaged bone and the injury of osteocytes may 
be the event that stimulates osteoclastic resporption. In fact, damaged osteocytes secrete M-
CSF and RANKL that promote osteoclast differentiation (Kurata et al, 2006). Bone resorption 
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occurs with the formation of the ruffled border composed of finger-shaped projections of the 
osteoclast membrane that mediates the process. The ruffled border forms on the surface of 
the bone and is only present when active resorption is occurring. This structure is also 
surrounded by a “clear zone”, to form a microenvironment that defines the area destined to 
be resorbed. The mineral is dissolved through the action of an ATP-driven proton pump 
located in the membrane of the ruffled border. ECM, such as collagen and non-collagenous 
proteins are degraded through the action of MMPs, tartrate resistance acid phosphatase 
(TRAP) and cathespins K, B and L that are secreted by the osteoclast into the resorptive area 
(Bossard et al, 1996). Degraded protein components are endocytosed along the ruffled 
border within resorption lacunae, which are then transported to the membrane on the 
opposite side for release (Nesbitt et al, 1997).  
4. Tissue engineering approaches and future perspectives 
As highlighted above autogenous bone grafting is the most common surgical approach to 
treat bone defects however it does have its drawbacks including failure and rejection. There 
are three fundamental requirements for tissue regeneration to ensure the formation of good 
quality tissues that can withstand the demands of normal function: i) a source of cells to 
drive the regenerative process; ii) a source of growth factors and nutrients; and iii) a suitable 
biomaterial which can support and sustain the growth of the new tissue. However, 
obtaining these three components remains a challenge to tissue engineers.  
4.1 Biomaterials 
Several important properties, biological and physical, must be considered when developing 
and choosing the “ideal” biomaterial for bone grafting and regeneration procedures. The 
material should provide stability and possess the ability to promote osteogenesis. Physical 
properties include the ability to be sterilized, slow degradation rate, a high initial stiffness, a 
load-bearing capacity; it should be easily processed into complex-shapes and storable. 
Biologically, the material should be bioresorbable, biocompatible, capable of 
revascularization, with a highly porous and interconnected pore network to facilitate the 
flow and transport of nutrients and metabolic waste. In addition, the biomaterial should be 
either osteoconductive or osteoinductive. Osteoconductive materials act as a scaffold and 
the grafted material does not contribute to new bone formation per se. As a result an 
osteoconductive material enhances native bone formation in an orthotopic site. Whereas, 
with an osteoinductive material, it can induce bone formation in an ectopic site, in the 
surrounding soft tissue immediately adjacent to the grafted material by release of growth 
factors or other stimulatory mediators. 
Four types of bone graft or substitute materials are available, autogeneous, allogenic, 
xenogeneic grafts and alloplastic materials. Autogeneous grafts have already been 
discussed, however it should be highlighted that this type of bone graft are the most 
osteoinductive and there is little immunological rejection. In addition, a surgical donor site 
is required and these tend to have a high morbidly rate. Alternatively, allogeneic grafts are 
widely used and occur between genetically dissimilar members of the same species. 
Typically frozen cancellous or freeze-dried demineralized bone is used. These grafts are 
both osteoconductive and osteoinductive but there is the possibility of disease transmission, 






immunological response. Xenogeneic grafts are widely used, whereby the material is taken 
from the donor of another species, for example bovine. These materials are osteoconductive 
and do show some potential for osteoinduction but again there is the potential for disease 
transmission. The final type of bone graft materials are the bone fillers, synthetic or 
inorganic alloplastic materials that are used as bone substitutes, including HAP, β-tricalcium 
phosphate, polymers and bioactive glass. It remains a challenge for the bioengineers to 
develop a suitable biomaterial to stimulate regeneration. Modifications to provide a 
biomimetic surface are a particular area of study. To facilitate cell attachment is one 
example, and many modifications exploit cell binding motifs, such as the RGD-sequence. 
4.2 Cells 
In addition to the bone-building materials outlined above, the cell source has been a 
considerable focus in regenerative strategies. Obtaining sufficient numbers of cells with the 
appropriate phenotype has been a considerable challenge to the field of regenerative medicine. 
Ideally endogenous cells from the surrounding milieu would migrate into the defect area in 
the presence of a scaffold or support by cell homing. Indeed, osteoblasts may migrate from an 
autologous bone graft to stimulate bone formation. However, allograft, xenograft or synthetic 
materials lack this cell population and may require the additional application of cells. To 
produce bone from human stem cells could be a way to minimize the morbidity side effects. 
Adult stem cells have been at the forefront of regenerative medicine, in particular bone 
marrow-derived MSCs. However, limitations exist to using these cells as they are difficult to 
obtain in sufficient number due to technical problems and they are “tissue or organ-specific”. 
Pluripotent stem cells have revolutionized stem cell research and will in all likelihood have an 
immense impact on the treatment of various diseases in the future. At present, groups are 
studying the cell lines characteristics, and developing directed differentiation strategies to the 
required cell type. Pluripotent stem cells, human embryonic stem cells (HSEC) or induced 
pluripotent stem cells (iPSCs) could overcome the obstacles hampering adult stem cell 
therapies. This is particularly true since derivation and culture methods have advanced 
considerably, and cell lines now exist that are xeno-free and could potentially be used for 
therapeutic purposes if the correct differentiation pathways were established.  
A considerable number of studies have been performed on HESCs to induce osteogenic 
differentiation with many different approaches being taken (reviewed by Brown et al, 2011). 
Many groups have performed direct osteogenic differentiation, whereas others have taken 
the cells through a MSC progenitor stage prior to osteoblasts (Arpornmaeklong et al, 2009; 
Brown et al, 2009; Karp et al, 2006). Our own studies have shown that HESC lines 
differentiate along the osteogenic lineage, forming a fully mineralized bone-like matrix 
(Kärner et al, 2009; Kärner et al, 2007). We demonstrated the osteoblast phenotype using a 
large panel of extracellular matrix molecules and transcription factors (Kärner et al, 2007), 
and showed the dynamic gene expression of these markers (Kärner et al, 2009). In addition 
we characterized the deposited mineral with Fourier InfraRed spectroscopy proving that it 
resembled natural bone and was formed by cell-mediated mineralization. From these 
studies, we established a model system by which to define pluripotent stem cell osteogenic 
differentiation. Many technical difficulties remain be to overcome using HESCs 
therapeutically, as patient-matched or disease-specific HESCs will be difficult to generate, in 
addition to the many ethical issues to consider. One major break-through and potential 
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solution to the problems associated with HESCs has been the derivation of iPSCs, which 
could eventually lead to patient-matched tissue regeneration treatments such as bone. 
Whether iPSCs behave in a similar manner as HESCs in terms of osteogenic differentiation 
remains to be determined, however the osteogenic capacity of mouse iPSCs to regenerate 
bone has recently been established (Bilousova et al, 2011).  
Recent studies have shown that transplantation of bone grafts from a site of mesoderm 
tissue, such as the case of bone grafting onlay techniques, taking bone from the iliac crest to 
the mandible, which is neural crest derived contributes to the failure of the graft to fully 
integrate and regenerate bone to the standard required to withstand compressive functional 
processes (Chan et al, 2009; Leucht et al, 2008). These studies showed that the cell 
populations were not interchangeable, in that mesoderm-derived cells grafted into tibia 
defects produced osteoblasts but when transplanted into the mandible formed 
chondrocytes, and the reverse was true for neural crest-derived cells. The authors also 
reported that this regeneration was attributable to the homeobox gene expression pattern 
during embryonic development and referred to this phenomenon referred to as “positional 
memory” (Leucht et al, 2008). Such a finding is of considerable importance to the field of 
regenerative medicine, and techniques used for bone grafting procedures. 
4.3 Growth factors  
The ability to retain and release growth factors into the surrounding environment is crucial 
to ensure that cells home to the site of tissue repair and to stimulate regeneration. This has 
been a limiting factor to the field of tissue engineering and many obstacles remain to be 
overcome, including, identification of the ideal carrier, how can we sequester the growth 
factors to the carrier so that they remain biologically active and what is the correct dosage of 
the factor? Many of the growth factors are recombinantly produced, such as the BMPs and 
at present the amounts used for regeneration are significantly larger than those 
endogenously present. Adding to this is the huge cost of producing such large amounts of 
recombinant protein in a highly purified form.  
Growth factors that are commonly used for bone regeneration include BMPs, TGF-β, FGF, 
VEGF, IGF, PDGF, EGF, PTH / PTH (related protein) (PTHrP) and interleukins. BMPs are 
involved in many developmental processes but these factors have been most widely studied 
in terms of bone engineering and bone replacement. Osteoblasts synthesize BMPs and 
sequester them in the ECM. BMPs are osteoinductive molecules and when placed 
ectopically they can initiate the whole pathway of bone formation from MSC differentiation 
to the entrapment of terminally differentiated osteoblasts as osteocytes (Wozney et al, 1988). 
Typically they are used in combination with many of the other factors or in combination 
with other family members. BMP2 and 7 have been successfully used together to facilitate 
boney healing (Koh et al, 2008;Ripamonti et al, 1997). The use of TGF-β’s for bone 
regeneration has been extensively evaluated and show both stimulatory and inhibitory 
effects on bone formation. Despite differences in experimental setups, combined TGF-β / 
BMP studies show additive or synergistic effects on bone formation (Si et al, 1998; Sumner et 
al, 2006). 
Although in many studies it has been shown that just one of these factors has been adequate 






natural healing process many growth factors and signaling molecules are involved 
simultaneously or through a cascade of events and to date it has not been possible to 
recapitulate this. A combination of several factors is likely to be more effective to assist 
boney healing.  
5. Conclusions 
This paper brings together clinical concepts and novel findings to the field of bone 
regeneration and highlights some considerations necessary when devising new strategies to 
treat oral-facial hard tissue defects. It is apparent from the studies described above that 
individuals respond differentially to stimulus; therefore future tissue engineering 
approaches with biomaterials, cells or growth factors will need to be tailored to the patient.  
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